Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of tisotumab vedotin in platinum-resistant ovarian cancer with a safety run-in
2019-001219-22Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Sep 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tisotumab vedotin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Seagen Inc. Primary endpoints: Safety and tolerability of dose-dense tisotumab vedotin regimen and Safety and tolerability of tisotumab vedotin. Started Sep 2019; status: terminated.
02
Drugs
tisotumab vedotin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2019-001219-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001219-22.